Modelling the resource implications of managing adults with Fabry disease in Norway favours home infusion

European Journal of Clinical Investigation

Volumn 40, Issue 12, 2010, Pages 1104-1112

  Guest, Julian F ^a,b   Jenssen, Trond ^c,d   Houge, Gunnar ^e,f   Aaseboe, Willy ^c   Tøndel, Camilla ^e,f   Svarstad, Einar ^e,f  

^a CATALYST Health Economics Consultants   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF TROMSØ   (Norway)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF BERGEN   (Norway)

Author keywords

Agalsidase alfa; Agalsidase beta; Cost; Fabrazyme; Fabry disease; Norway; Replagal

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG WITHDRAWAL; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; GENERAL PRACTITIONER; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; NORWAY; PRIORITY JOURNAL;

ADULT; ALPHA-GALACTOSIDASE; BUDGETS; COHORT STUDIES; FABRY DISEASE; HEALTH CARE COSTS; HEALTH CARE RATIONING; HEALTH RESOURCES; HOME CARE SERVICES; HOME INFUSION THERAPY; HUMANS; ISOENZYMES; MODELS, ECONOMIC; NORWAY; RESOURCE ALLOCATION;

EID: 78649426034     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02363.x     Document Type: Article

References (43)

1. Peters FPJ, Vermeulen A, Kho TL. Anderson-Fabry's disease: α-galactosidase deficiency. Lancet 2001;357:138-40.
2. Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C et al. Fabry disease defined: baseline clinical manifestations of 366 patients in FOS - the Fabry Outcome Survey. Eur J Clin Invest 2004;34:236-42.
3. Ries M, Ramaswami U, Parini R, Lindblad B, Whybra C, Willers I et al. The early clinical phenotype of Fabry disease: a study of 35 European children. Eur J Pediatr 2003;162:767-72.
4. Mehta A, Clarke JT, Giugliani R, Elliott P, Linhart A, Beck M et al. Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. J Med Genet 2009;46:548-52.
5. European Organisation for Rare Diseases 2009. Available at Accessed on 30 September 2009.
6. Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS et al., editors. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 2001: pp 37-74.
7. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54.
8. Houge G, Skarbøvik AJ. Fabry disease - a diagnostic and therapeutic challenge. Tidsskr Nor Laegeforen 2005;125:1004-6.
9. Grabowski GA, Leslie N, Wenstrup R. Enzyme therapy for Gaucher disease: the first 5 years. Blood Rev 1998;12:115-33.
10. Moore DF, Herscovitch P, Schiffmann R. Selective arterial distribution of cerebral hyperperfusion in Fabry disease. J Neuroimaging 2001;11:303-7.
11. Moore DF, Scott LT, Gladwin MT, Altarescu G, Kaneski C, Suzuki K et al. Regional cerebral hyperperfusion and nitric oxide pathway deregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 2001;104:1506-12.
12. Moore DF, Altarescu G, Ling GS, Jeffries N, Frei KP, Weibel T et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 2002;33:525-31.
13. West M, Nicholls K, Mehta A, Clarke JT, Steiner R, Beck M et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 2009;20:1132-9.
14. Beck M. Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety. Expert Opin Biol Ther 2009;9:255-61.
15. Hoffmann B, Garcia de Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R; FOS European Investigators. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet 2005;42:247-52.
16. Hajioff D, Enever Y, Quiney R, Zuckerman J, Mackermot K, Mehta A. Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy. J Inherit Metab Dis 2003;26:787-94.
17. Waldek S. PR interval and the response to enzyme-replacement therapy for Fabry's disease. N Engl J Med 2003;348:1186-7.
18. Germain DP, Waldek S, Banikazemi M, Bushinsky DA, Charrow J, Desnick RJ et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007;18:1547-57.
19. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M et al. Fabry Disease Clinical Trial Study Group. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007;146:77-86.
20. Johnsen JR. Health Systems in Transition: Norway. Copenhagen: WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies; 2006.
21. NAV 2009. Available on line at Accessed on 30 September 2009.
22. OECD Health Data 2008. Available online at Accessed on 30 September 2009.
23. Drummond M, Evans B, LeLorier J, Karakiewicz P, Martin D, Tugwell P et al. Evidence and values: requirements for public reimbursement of drugs for rare diseases - a case study in oncology. Can J Clin Pharmacol 2009;16:e273-81; discussion e282-4. Epub 2009.
24. Linthorst GE, Vedder AC, Ormel EE, Aerts JM, Hollak CE. Home treatment for Fabry disease: practice guidelines based on 3 years experience in The Netherlands. Nephrol Dial Transplant 2006;21:355-60.
25. Milligan A, Hughes D, Goodwin S, Richfield L, Mehta A. Intravenous enzyme replacement therapy: better in home or hospital? Br J Nurs 2006;15:330-3.
26. Lee K, Jin X, Zhang K, Copertino L, Andrews L, Baker-Malcolm J et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 2003;13:305-13.
27. Sakuraba H, Murata-Ohsawa M, Kawashima I, Tajima Y, Kotani M, Ohshima T et al. Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice. J Hum Genet 2005;51:180-8.
28. Pastores GM, Thadhani R. Enzyme-replacement therapy for Anderson-Fabry disease. Lancet 2001;358:601-3.
29. Bengtsson BA, Johansson JO, Hollak C, Linthorst G, FeldtRasmussen U. Enzyme replacement in Anderson-Fabry disease. Lancet 2003;361:352.
30. Hopkin RJ, Bissler J, Grabowski GA. Comparative evaluation of alphagalactosidase A infusions for treatment of Fabry disease. Genet Med 2003;5:144-53.
31. Desnick RJ. Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval. Expert Opin Biol Ther 2004;4:1167-76.
32. Mignani R, Cagnoli L. Enzyme replacement therapy in Fabry's disease: recent advances and clinical applications. J Nephrol 2004;17:354-63.
33. Schiffmann R, Kopp JB, Austin HA, Sabnis S, Moore DF, Weibel T et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743-9.
34. Schiffmann R, Floeter MK, Dambrosia JM, Gupta S, Moore DF, Sharabi Y et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 2003;28:703-10.
35. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 2006;21:345-54.
36. Feriozzi S, Schwarting A, Sunder-Plassmann G, West M, Cybulla M; International Fabry Outcome Survey Investigators. Agalsidase alfa slows the decline in renal function in patients with Fabry disease. Am J Nephrol 2009; 29: 353-61.
37. Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004;75:65-74.
38. Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003;108:1299-301.
39. Spinelli L, Pisani A, Sabbatini M, Petretta M, Andreucci MV, Procaccini D et al. Enzyme replacement therapy with agalsidase b improves cardiac involvement in Fabry's disease. Clin Genet 2004;66:158-65.
40. Lidove O, Joly D, Barbey F, Bekri S, Alexandra JF, Peigne V et al. Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Int J Clin Pract 2007;61:293-302.
41. Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS ONE 2007;2:e598.
42. Whybra C, Miebach E, Mengel E, Gal A, Baron K, Beck M et al. A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease. Genet Med 2009;11:441-9.
43. Bodensteiner D, Scott CR, Sims KB, Shepherd GM, Cintron RD, Germain DP. Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme. Genet Med 2008;10:353-8.